Fluoxetine for the symptomatic treatment of Multiple System Atrophy : the MSA-FLUO trial

Abstract: Background: There are no effective treatments for multiple system atrophy (MSA). Objective: The objective of this study was to assess the efficacy and safety of the serotonin reuptake inhibitor fluoxetine (40 mg/d) for the symptomatic treatment of MSA. Methods: This was a double-blind, parallel-group, placebo-controlled, randomized trial in patients with "probable" MSA. The primary outcome was the change from baseline to week 12 in the mean total score of the Unified MSA Rating Scale (UMSARS Parts I + II). Secondary outcomes included change from baseline to week 6 in total UMSARS, and change from baseline to week 12 in the Scales for Outcomes in Parkinson Disease-Autonomic Dysfunction, Beck Depression Inventory, and different domains of the MSA-Quality of Life Questionnaire. Exploratory outcomes included change from baseline to week 12 in the UMSARS Parts I and II separately and change from baseline to week 24 in the total UMSARS score. Results: A total of 81 patients were randomly assigned, with no significant difference in the primary outcome (-2.13 units [95% confidence interval, CI, -4.55 to 0.29]; P = 0.08). There was a greater reduction on fluoxetine in the change from baseline to 12-week in UMSARS Part II (exploratory outcome: -1.41 units [95% CI, -2.84; 0.03]; p = 0.05) and in MSA-QoL emotional/social dimension (secondary outcome: -6.99 units [95% CI, -13.40; -0.56]; p < 0.03). A total of 5 deaths occurred (3 on fluoxetine and 2 on placebo). Conclusion: The MSA-FLUO failed to demonstrate fluoxetine superiority over placebo on the total UMSARS score, whereas trends in motor and emotional secondary/exploratory outcomes deserve further investigation.

Saved in:
Bibliographic Details
Main Authors: Rascol, Olivier, Cochen De Cock, Valérie, Pavy-Le Traon, Anne, Foubert Samier, Alexandra, Thalamas, Claire, Sommet, Agnès, Rousseau, Vanessa, Pérez Lloret, Santiago, Fabbri, Margherita, Azulay, Jean Philippe, Corvol, Jean-Christophe, Couratier, Philippe, Damier, Philippe, Defebvre, Luc, Durif, Franck, Geny, Christian, Houeto, Jean-Luc, Remy, Philippe, Tranchant, Christine, Verin, Marc, Tison, François, Meissner, Wassilios G.
Format: Artículo biblioteca
Language:eng
Published: Wiley 2021
Subjects:NEUROBIOLOGIA, ENFERMEDADES NEURODEGENERATIVAS, ENFERMEDAD DE PARKINSON, ENSAYO CLINICO, TRATAMIENTO MEDICO, ATROFIA MULTISISTÉMICA,
Online Access:https://repositorio.uca.edu.ar/handle/123456789/11645
Tags: Add Tag
No Tags, Be the first to tag this record!
id oai:ucacris:123456789-11645
record_format koha
spelling oai:ucacris:123456789-116452024-03-21T11:57:44Z Fluoxetine for the symptomatic treatment of Multiple System Atrophy : the MSA-FLUO trial Rascol, Olivier Cochen De Cock, Valérie Pavy-Le Traon, Anne Foubert Samier, Alexandra Thalamas, Claire Sommet, Agnès Rousseau, Vanessa Pérez Lloret, Santiago Fabbri, Margherita Azulay, Jean Philippe Corvol, Jean-Christophe Couratier, Philippe Damier, Philippe Defebvre, Luc Durif, Franck Geny, Christian Houeto, Jean-Luc Remy, Philippe Tranchant, Christine Verin, Marc Tison, François Meissner, Wassilios G. NEUROBIOLOGIA ENFERMEDADES NEURODEGENERATIVAS ENFERMEDAD DE PARKINSON ENSAYO CLINICO TRATAMIENTO MEDICO ATROFIA MULTISISTÉMICA Abstract: Background: There are no effective treatments for multiple system atrophy (MSA). Objective: The objective of this study was to assess the efficacy and safety of the serotonin reuptake inhibitor fluoxetine (40 mg/d) for the symptomatic treatment of MSA. Methods: This was a double-blind, parallel-group, placebo-controlled, randomized trial in patients with "probable" MSA. The primary outcome was the change from baseline to week 12 in the mean total score of the Unified MSA Rating Scale (UMSARS Parts I + II). Secondary outcomes included change from baseline to week 6 in total UMSARS, and change from baseline to week 12 in the Scales for Outcomes in Parkinson Disease-Autonomic Dysfunction, Beck Depression Inventory, and different domains of the MSA-Quality of Life Questionnaire. Exploratory outcomes included change from baseline to week 12 in the UMSARS Parts I and II separately and change from baseline to week 24 in the total UMSARS score. Results: A total of 81 patients were randomly assigned, with no significant difference in the primary outcome (-2.13 units [95% confidence interval, CI, -4.55 to 0.29]; P = 0.08). There was a greater reduction on fluoxetine in the change from baseline to 12-week in UMSARS Part II (exploratory outcome: -1.41 units [95% CI, -2.84; 0.03]; p = 0.05) and in MSA-QoL emotional/social dimension (secondary outcome: -6.99 units [95% CI, -13.40; -0.56]; p < 0.03). A total of 5 deaths occurred (3 on fluoxetine and 2 on placebo). Conclusion: The MSA-FLUO failed to demonstrate fluoxetine superiority over placebo on the total UMSARS score, whereas trends in motor and emotional secondary/exploratory outcomes deserve further investigation. 2021-06-17T17:54:44Z 2021-06-17T17:54:44Z 2021 Artículo Rascol, O., et al. Fluoxetine for the symptomatic treatment of Multiple System Atrophy : the MSA-FLUO trial [en línea]. Postprint del artículo publicado en: Movement Disorders. 2021. doi: 10.1002/mds.28569. Disponible en: https://repositorio.uca.edu.ar/handle/123456789/11645 1531-8257 https://repositorio.uca.edu.ar/handle/123456789/11645 10.1002/mds.28569 eng Acceso abierto. 12 meses de embargo http://creativecommons.org/licenses/by-nc-sa/4.0/ application/pdf Wiley Postprint del artículo publicado en: Movement Disorders. 2021
institution UCA
collection DSpace
country Argentina
countrycode AR
component Bibliográfico
access En linea
databasecode dig-uca
tag biblioteca
region America del Sur
libraryname Sistema de bibliotecas de la UCA
language eng
topic NEUROBIOLOGIA
ENFERMEDADES NEURODEGENERATIVAS
ENFERMEDAD DE PARKINSON
ENSAYO CLINICO
TRATAMIENTO MEDICO
ATROFIA MULTISISTÉMICA
NEUROBIOLOGIA
ENFERMEDADES NEURODEGENERATIVAS
ENFERMEDAD DE PARKINSON
ENSAYO CLINICO
TRATAMIENTO MEDICO
ATROFIA MULTISISTÉMICA
spellingShingle NEUROBIOLOGIA
ENFERMEDADES NEURODEGENERATIVAS
ENFERMEDAD DE PARKINSON
ENSAYO CLINICO
TRATAMIENTO MEDICO
ATROFIA MULTISISTÉMICA
NEUROBIOLOGIA
ENFERMEDADES NEURODEGENERATIVAS
ENFERMEDAD DE PARKINSON
ENSAYO CLINICO
TRATAMIENTO MEDICO
ATROFIA MULTISISTÉMICA
Rascol, Olivier
Cochen De Cock, Valérie
Pavy-Le Traon, Anne
Foubert Samier, Alexandra
Thalamas, Claire
Sommet, Agnès
Rousseau, Vanessa
Pérez Lloret, Santiago
Fabbri, Margherita
Azulay, Jean Philippe
Corvol, Jean-Christophe
Couratier, Philippe
Damier, Philippe
Defebvre, Luc
Durif, Franck
Geny, Christian
Houeto, Jean-Luc
Remy, Philippe
Tranchant, Christine
Verin, Marc
Tison, François
Meissner, Wassilios G.
Fluoxetine for the symptomatic treatment of Multiple System Atrophy : the MSA-FLUO trial
description Abstract: Background: There are no effective treatments for multiple system atrophy (MSA). Objective: The objective of this study was to assess the efficacy and safety of the serotonin reuptake inhibitor fluoxetine (40 mg/d) for the symptomatic treatment of MSA. Methods: This was a double-blind, parallel-group, placebo-controlled, randomized trial in patients with "probable" MSA. The primary outcome was the change from baseline to week 12 in the mean total score of the Unified MSA Rating Scale (UMSARS Parts I + II). Secondary outcomes included change from baseline to week 6 in total UMSARS, and change from baseline to week 12 in the Scales for Outcomes in Parkinson Disease-Autonomic Dysfunction, Beck Depression Inventory, and different domains of the MSA-Quality of Life Questionnaire. Exploratory outcomes included change from baseline to week 12 in the UMSARS Parts I and II separately and change from baseline to week 24 in the total UMSARS score. Results: A total of 81 patients were randomly assigned, with no significant difference in the primary outcome (-2.13 units [95% confidence interval, CI, -4.55 to 0.29]; P = 0.08). There was a greater reduction on fluoxetine in the change from baseline to 12-week in UMSARS Part II (exploratory outcome: -1.41 units [95% CI, -2.84; 0.03]; p = 0.05) and in MSA-QoL emotional/social dimension (secondary outcome: -6.99 units [95% CI, -13.40; -0.56]; p < 0.03). A total of 5 deaths occurred (3 on fluoxetine and 2 on placebo). Conclusion: The MSA-FLUO failed to demonstrate fluoxetine superiority over placebo on the total UMSARS score, whereas trends in motor and emotional secondary/exploratory outcomes deserve further investigation.
format Artículo
topic_facet NEUROBIOLOGIA
ENFERMEDADES NEURODEGENERATIVAS
ENFERMEDAD DE PARKINSON
ENSAYO CLINICO
TRATAMIENTO MEDICO
ATROFIA MULTISISTÉMICA
author Rascol, Olivier
Cochen De Cock, Valérie
Pavy-Le Traon, Anne
Foubert Samier, Alexandra
Thalamas, Claire
Sommet, Agnès
Rousseau, Vanessa
Pérez Lloret, Santiago
Fabbri, Margherita
Azulay, Jean Philippe
Corvol, Jean-Christophe
Couratier, Philippe
Damier, Philippe
Defebvre, Luc
Durif, Franck
Geny, Christian
Houeto, Jean-Luc
Remy, Philippe
Tranchant, Christine
Verin, Marc
Tison, François
Meissner, Wassilios G.
author_facet Rascol, Olivier
Cochen De Cock, Valérie
Pavy-Le Traon, Anne
Foubert Samier, Alexandra
Thalamas, Claire
Sommet, Agnès
Rousseau, Vanessa
Pérez Lloret, Santiago
Fabbri, Margherita
Azulay, Jean Philippe
Corvol, Jean-Christophe
Couratier, Philippe
Damier, Philippe
Defebvre, Luc
Durif, Franck
Geny, Christian
Houeto, Jean-Luc
Remy, Philippe
Tranchant, Christine
Verin, Marc
Tison, François
Meissner, Wassilios G.
author_sort Rascol, Olivier
title Fluoxetine for the symptomatic treatment of Multiple System Atrophy : the MSA-FLUO trial
title_short Fluoxetine for the symptomatic treatment of Multiple System Atrophy : the MSA-FLUO trial
title_full Fluoxetine for the symptomatic treatment of Multiple System Atrophy : the MSA-FLUO trial
title_fullStr Fluoxetine for the symptomatic treatment of Multiple System Atrophy : the MSA-FLUO trial
title_full_unstemmed Fluoxetine for the symptomatic treatment of Multiple System Atrophy : the MSA-FLUO trial
title_sort fluoxetine for the symptomatic treatment of multiple system atrophy : the msa-fluo trial
publisher Wiley
publishDate 2021
url https://repositorio.uca.edu.ar/handle/123456789/11645
work_keys_str_mv AT rascololivier fluoxetineforthesymptomatictreatmentofmultiplesystematrophythemsafluotrial
AT cochendecockvalerie fluoxetineforthesymptomatictreatmentofmultiplesystematrophythemsafluotrial
AT pavyletraonanne fluoxetineforthesymptomatictreatmentofmultiplesystematrophythemsafluotrial
AT foubertsamieralexandra fluoxetineforthesymptomatictreatmentofmultiplesystematrophythemsafluotrial
AT thalamasclaire fluoxetineforthesymptomatictreatmentofmultiplesystematrophythemsafluotrial
AT sommetagnes fluoxetineforthesymptomatictreatmentofmultiplesystematrophythemsafluotrial
AT rousseauvanessa fluoxetineforthesymptomatictreatmentofmultiplesystematrophythemsafluotrial
AT perezlloretsantiago fluoxetineforthesymptomatictreatmentofmultiplesystematrophythemsafluotrial
AT fabbrimargherita fluoxetineforthesymptomatictreatmentofmultiplesystematrophythemsafluotrial
AT azulayjeanphilippe fluoxetineforthesymptomatictreatmentofmultiplesystematrophythemsafluotrial
AT corvoljeanchristophe fluoxetineforthesymptomatictreatmentofmultiplesystematrophythemsafluotrial
AT couratierphilippe fluoxetineforthesymptomatictreatmentofmultiplesystematrophythemsafluotrial
AT damierphilippe fluoxetineforthesymptomatictreatmentofmultiplesystematrophythemsafluotrial
AT defebvreluc fluoxetineforthesymptomatictreatmentofmultiplesystematrophythemsafluotrial
AT duriffranck fluoxetineforthesymptomatictreatmentofmultiplesystematrophythemsafluotrial
AT genychristian fluoxetineforthesymptomatictreatmentofmultiplesystematrophythemsafluotrial
AT houetojeanluc fluoxetineforthesymptomatictreatmentofmultiplesystematrophythemsafluotrial
AT remyphilippe fluoxetineforthesymptomatictreatmentofmultiplesystematrophythemsafluotrial
AT tranchantchristine fluoxetineforthesymptomatictreatmentofmultiplesystematrophythemsafluotrial
AT verinmarc fluoxetineforthesymptomatictreatmentofmultiplesystematrophythemsafluotrial
AT tisonfrancois fluoxetineforthesymptomatictreatmentofmultiplesystematrophythemsafluotrial
AT meissnerwassiliosg fluoxetineforthesymptomatictreatmentofmultiplesystematrophythemsafluotrial
_version_ 1794795108229447680